Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$3.77 - $42.00
Previous CloseN/A
Volume318.06K
Average Volume (3M)1.46M
Market Cap
$312.62M
Enterprise Value$6.75M
Total Cash (Recent Filing)$8.12M
Total Debt (Recent Filing)$139.00K
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Aug 17, 2026EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.98
Shares Outstanding68,693,054
10 Day Avg. Volume2,983,897
30 Day Avg. Volume1,463,028
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.28
Price to Sales (P/S)11.48
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$1.00Price Target Upside16.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.96
Revenue Forecast (FY)$6.37M
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ValidationFDA marketing authorization and an FDA‑approved 30‑site ChoICE post‑market study create durable clinical validation. This regulatory backing eases hospital adoption, supports payer engagement over time, and supplies real‑world outcomes that reduce clinical uncertainty and enable broader market access.
Commercial Traction & Installed Base GrowthRapid account additions and double‑digit revenue growth signal that FDA clearance is translating into system placements and recurring consumable demand. A growing installed base strengthens future recurring revenue potential and validates the sales model as the company scales its U.S. commercial organization.
Conservative Leverage / Strong Solvency ProfileVery low debt and positive equity reduce near‑term solvency risk, giving management flexibility to invest in commercialization and clinical programs without immediate debt pressures. This balance sheet conservatism supports multi‑quarter commercialization plans and lowers refinancing urgency.
Bears Say
High Cash BurnCash burn far exceeds current revenue (~$3.6M TTM), meaning internal cash generation cannot fund growth. Persistent negative operating and free cash flow creates ongoing financing dependency, raising dilution risk and pressuring execution if equity markets or ATM programs are constrained.
Profound UnprofitabilityVery large losses relative to modest revenues indicate a cost structure not yet scalable to current sales. Continued negative profitability erodes equity and investor flexibility, forcing tradeoffs between funding commercialization, clinical studies and R&D until material margin improvement is achieved.
Reimbursement Timing & UncertaintyPayer decisions and potential pass‑through payments materially affect procedure economics and provider adoption. Multi‑year timing and conditional approvals can delay broader uptake, limit office‑based growth, and lengthen the conversion timeline from leads to durable system and consumable revenue.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $3.77 and its highest was $42.00 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $312.62M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 72 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on May 12, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.4 by -$0.4.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -1.5.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 68,693,054 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.4. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icecure Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.00 (16.28% Upside)
$1.00 (16.28% Upside)
Hedge Fund Trend
Decreased
By 384.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 12.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.78%
12-Months-Change
Fundamentals
Return on Equity
-211.73%
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
Icecure Medical Ltd.
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
ICCM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong positive momentum driven by 26% revenue growth, outsized North America (84%) and U.S. (31%) gains, FDA clearance, increasing active accounts (+46%), an approved 30‑site Choice post‑market study, and expanding commercial and clinical validation. Key near‑term risks include reimbursement timing (CPT‑1 and pass‑through uncertainty), limitations for office‑based reimbursement, and multi‑quarter conversion timelines for leads to system sales. On balance, the positives (regulatory milestone, accelerating sales, study approval and pipeline growth) outweigh the challenges, while some execution and reimbursement risks remain.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$1.00
▲(16.28% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
4.14% Other Institutional Investors
95.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---